SOUTH
SAN FRANCISCO, Calif., Jan. 27,
2025 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(NASDAQ: IDYA), a precision medicine oncology company committed to
the discovery and development of targeted therapeutics, announced
its participation in the upcoming investor relations events.
Oppenheimer 35th Annual Healthcare Life Sciences
Conference
Tuesday, February 11th,
2025 at 1:20 PM ET
- Fireside chat with Yujiro S. Hata, President and Chief
Executive Officer, hosted by Matthew Biegler, Executive
Director and Senior Analyst
Citi's 2025 Virtual Oncology Leadership Summit
Wednesday, February 19th,
2025 at 12:00 PM ET
- Fireside chat with Yujiro S.
Hata, President and Chief Executive Officer, hosted
by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech
Analyst
A live audio webcast of the conference event, as permitted by
the conference host, will be available under the "Investors/Events"
section of the IDEAYA website at
https://ir.ideayabio.com/events and/or through the conference host.
A replay of the webcast will be accessible for 30 days following
the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's
approach integrates capabilities in identifying and validating
translational biomarkers with drug discovery to select patient
populations most likely to benefit from its targeted therapies.
IDEAYA is applying its early research and drug discovery
capabilities to synthetic lethality – which represents an emerging
class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to participation
in and/or presentation at certain investor relations events. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's current
and future filings with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 10-K filed on
February 20, 2024.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-february-2025-investor-relations-events-302360092.html
SOURCE IDEAYA Biosciences, Inc.
